麻豆成人精品国产免费,日本午夜精品一区二区三区电影 ,亚洲处破女av日韩精品

您好，歡迎光臨上海雅吉生物商城！

工作時間：9:00-18:00

全國服務熱線：021-34661276

商品詳情
售后服務
相關文獻

產品編號	bs-0623R
英文名稱	Rabbit　Anti-Cyclin D1　antibody
中文名稱	周期素D1抗體
別　　　　名	CyclinD1; Cyclin-D1; B cell ccl/lymphoma 1; B cell leukemia 1; B-cell CLL/lymphoma 1; B-cell leukemia 1; B-cell lymphoma 1 protein; BCL-1; BCL1; BCL1 oncogene; CCND 1; CCND1; CCND1 protein; CCND1/FSTL3 fusion gene, included; CCND1/IGHG1 fusion gene; CCND1/IGHG1 fusion gene, included; CCND1/IGLC1 fusion gene, included; CCND1/PTH fusion gene, included; Parathyroid adenomatosis 1; PRAD1; FSTL3; CCND1_HUMAN; AI327039; B cell lymphoma 1 protein; BCL 1; BCL-1; BCL-1 oncogene; BCL1 oncogene; CCND1/FSTL3 fusion gene, included; cD1; Cyl 1; D11S287E; G1/S specific cyclin D1; G1/S-specific cyclin-D1.
	Specific References　　(72)　　　　　\|　　　　　bs-0623R has been referenced in 72 publications. [IF=14.903]　Luchen Sun. et al. A novel mesenchymal stem cell-based regimen for acute myeloid leukemia differentiation therapy. ACTA PHARM SIN B. 2023 May;:　　WB　;　　Human.　　 PubMed:10.1016/j.apsb.2023.05.007 [IF=13.273]　Long Zhao. et al. Juglone-loaded metal-organic frameworks for H2O2 self-modulating enhancing chemodynamic therapy against prostate cancer. Chem Eng J. 2022 Feb;430:133057　　WB　;　　Human.　　 PubMed:10.1016/j.cej.2021.133057 [IF=9.429]　Li, Guang. et al. Synergetic delivery of artesunate and isosorbide 5-mononitrate with reduction-sensitive polymer nanoparticles for ovarian cancer chemotherapy. J NANOBIOTECHNOL. 2022 Dec;20(1):1-13　　WB　;　　Human.　　 PubMed:36335352 [IF=8.755]　Sijie Wang. et al. PFKFB4 facilitates palbociclib resistance in oestrogen receptor-positive breast cancer by enhancing stemness. CELL PROLIFERAT. 2022 Sep;:e13337　　WB　;　　Human.　　 PubMed:36127291 [IF=8.74]　Chen et al. STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7. (2015) Cancer.Cell.Int. 15:111　　WB　;　　Human.　　 PubMed:26617467 [IF=8.469]　Que, Tianshi. et al. HMGA1 stimulates MYH9-dependent ubiquitination of GSK-3β via PI3K/Akt/c-Jun signaling to promote malignant progression and chemoresistance in gliomas. Cell Death Dis. 2021 Dec;12(12):1-12　　WB　;　　Human.　　 PubMed:34887392 [IF=7.6]　Teng, I., et al. "Phospholipid-functionalized mesoporous silica nanocarriers for selective photodynamic therapy of cancer." Biomaterials (2013).　　WB　;　　Mouse.　　 PubMed:23810081 [IF=7.109]　Liu, Yuan-Rong. et al. Oncogenic TRIB2 interacts with and regulates PKM2 to promote aerobic glycolysis and lung cancer cell procession. CELL DEATH DISCOV. 2022 Jul;8(1):1-12　　WB　;　　Human.　　 PubMed:35790734 [IF=7.077]　Xinrui Li. et al. Skeletal muscle mass, meat quality and antioxidant status in growing lambs supplemented with guanidinoacetic acid. MEAT SCI. 2022 Oct;192:108906　　WB　;　　Sheep.　　 PubMed:35850029 [IF=6.543]　Zhou Wan. et al. The Effects of RBP4 and Vitamin D on the Proliferation and Migration of Vascular Smooth Muscle Cells via the JAK2/STAT3 Signaling Pathway. Oxid Med Cell Longev. 2022;2022:3046777　　WB　;　　Rat.　　 PubMed:35082965 [IF=6.208]　Molin Li. et al. PPP3R1 Promotes MSCs Senescence by Inducing Plasma Membrane Depolarization and Increasing Ca2+ Influx. INT J MOL SCI. 2023 Jan;24(5):4421　　WB　;　　Mouse.　　 PubMed:36901851 [IF=6.064]　Shimaa Abdelsattar. et al. The Potential Utility of Circulating Oncofetal H19 Derived miR-675 Expression versus Tissue lncRNA-H19 Expression in Diagnosis and Prognosis of HCC in Egyptian Patients. BIOMOLECULES. 2023 Jan;13(1):3　　IHC　;　　Human.　　 PubMed:36671388 [IF=6.044]　Li Y et al. Apple polysaccharide protects ICR mice against colitis associated colorectal cancer through the regulation of microbial dysbiosis. Carbohydr Polym. 2020 Feb 15;230:115726.　　WB　;　　Mouse&Human.　　 PubMed:31887919 [IF=5.17]　Wu et al. The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. (2015) Oncotarge. 6:9160-72　　WB　;　　Human.　　 PubMed:25863539 [IF=5.17]　Liang et al. Histone demethylase RBP2 induced by Helicobactor Pylori CagA participates in the malignant transformation of gastric epithelial cells. (2014) Oncotarge. 5:5798-807　　WB, IHC　;　　Human.　　 PubMed:25015565 [IF=4.92]　Carreras et al. Chronic sleep fragmentation induces endothelial dysfunction and structural vascular changes in mice. (2014) Slee. 37:1817-24　　IHC-P　;　　Mouse.　　 PubMed:25364077 [IF=4.486]　Chen Y et al. PLK1 regulates hepatic stellate cell activation and liver fibrosis through Wnt/β‐catenin signalling pathway. J Cell Mol Med. 2020 Jul;24(13):7405-7416.　　WB　;　　Mouse&Human.　　 PubMed:32463161 [IF=4.375]　Zhang Hailin. et al. MicroRNA-2355-5p Promotes the Proliferation of Head and Neck Squamous Cell Carcinoma via Suppressing NISCH Expression. J Oncol. 2021;2021:2986489　　WB　;　　Human.　　 PubMed:10.1155/2021/2986489 [IF=4.302]　Ju B et al. miR-193a/b-3p?relieves?hepatic?fibrosis?and?restrains?proliferation?and?activation?of?hepaticstellate?cells. J Cell Mol Med.?2019 Apr 3.　　WB　;　　Human.　　 PubMed:30945448 [IF=4.175]　Junmin Li. et al. Circ_ZFR contributes to the paclitaxel resistance and progression of non-small cell lung cancer by upregulating KPNA4 through sponging miR-195-5p. Cancer Cell Int. 2021 Dec;21(1):1-15　　WB　;　　Human.　　 PubMed:33407505 [IF=4.114]　Hui-Zi Liu. et al. Silencing long non-coding RNA CASC9 inhibits colorectal cancer cell proliferation by acting as a competing endogenous RNA of miR-576-5p to regulate AKT3. Cell Death Discov. 2020 Oct;6(1):1-11　　WB　;　　Human.　　 PubMed:33298846 [IF=4.04]　Wang, Y., et al. "Elevated toll-like receptor 3 inhibits pancreatic b-cell proliferation through G1 phase cell cycle arrest." Molecular and Cellular Endocrinology (2013)　　Mouse.　　 PubMed:23850521 [IF=4.01]　Xiong Y et al. ZYZ-803, a novel hydrogen sulfide-nitric oxide conjugated donor, promotes angiogenesis via cross-talk between STAT3 and CaMKII. Acta Pharmacol Sin. 2019 Jul 17.　　WB　;　　Human.　　 PubMed:31316179 [IF=3.906]　Peng Gu. et al. Suppression of CDCA3 inhibits prostate cancer progression via NF?κB/cyclin D1 signaling inactivation and p21 accumulation. Oncol Rep. 2022 Feb;47(2):1-10　　WB　;　　Human.　　 PubMed:34970697 [IF=3.699]　 Zijian Ye . et al. MiR-92b-3p inhibits proliferation and migration of C2C12 cells. Cell Cycle. 2020;19(21):2906-2917　　WB　;　　Mouse.　　 PubMed:33043788 [IF=3.571]　Li X et al. Lysine enhances the stimulation of fatty acids on milk fat synthesis via the GPRC6A-PI3K-FABP5 signaling in bovine mammary epithelial cells. J Agric Food Chem. 2019 Jun 26;67(25):7005-7015.　　WB　;　　Cow.　　 PubMed:31174423 [IF=3.571]　Wang J et al. Influence of calcium supplementation against fluoride-mediated osteoblasts impairment in vitro: Involvement of canonical Wnt/β-catenin signaling pathway. J Agric Food Chem. 2019 Sep 4.　　WB　;　　Mouse.　　 PubMed:31443611 [IF=3.56]　Tan, Shi, et al. "Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway."Experimental Cell Research?(2013).　　WB　;　　Human.　　 PubMed:24076374 [IF=3.448]　Yang X et al. miR‐760 exerts an antioncogenic effect in esophageal squamous cell carcinoma by negatively driving fat metabolism via targeting c‐Myc. J Cell Biochem. 2019 Nov 10.　　WB　;　　Human.　　 PubMed:31709636 [IF=3.411]　Song Zhenyan. et al. Baicalin Attenuated Aβ1-42-Induced Apoptosis in SH-SY5Y Cells by Inhibiting the Ras-ERK Signaling Pathway. BIOMED RES INT. 2022;2022:9491755　　WB　;　　Human.　　 PubMed:35528169
研究領域	腫瘤　　細胞生物　　染色質和核信號　　細胞周期蛋白　　表觀遺傳學
抗體來源	Rabbit
克隆類型	Polyclonal
交叉反應	Human,Mouse,Rat (predicted: Dog)
產品應用	WB=1:500-2000, IHC-P=1:100-500, IHC-F=1:100-500, ICC=1:100, IF=1:100-500, Flow-Cyt=1μg/Test, ELISA=1:5000-10000 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
理論分子量	32kDa
細胞定位	細胞核　細胞漿　細胞膜
性　　　　狀	Liquid
濃　　　　度	1mg/ml
免　疫　原	KLH conjugated synthetic peptide derived from human Cyclin D1:　61-110/295
亞　　　　型	IgG
純化方法	affinity purified by Protein A
緩　沖　液	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件	Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
注意事項	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed	PubMed
產品介紹	The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis. [provided by RefSeq, Jul 2008]. Function: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma (RB)protein family including RB1 and regulates the cell-cycle duringG(1)/S transition. Phosphorylation of RB1 allows dissociation ofthe transcription factor E2F from the RB/E2F complex and thesubsequent transcription of E2F target genes which are responsiblefor the progression through the G(1) phase. Hypophosphorylates RB1in early G(1) phase. Cyclin D-CDK4 complexes are major integratorsof various mitogenenic and antimitogenic signals. Also substratefor SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent mannerand repressing its transcriptional activity. Component of theternary complex, cyclin D1/CDK4/CDKN1B, required for nucleartranslocation and activity of the cyclin D-CDK4 complex. Subunit: Interacts with FBXO4. Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation and modulationof CDK4-mediated kinase activity. Interacts directly with CDKN1B.Interacts with UHRF2; the interaction ubiquitinates CCND1 andappears to occur independently of phosphorylation. Can form similarcomplexes with either CDKN1A or CDKN2A. Interacts with USP2. Subcellular Location: Nucleus. Cytoplasm. Membrane. Note=CyclinD-CDK4 complexes accumulate at the nuclear membrane and are thentranslocated to the nucleus through interaction with KIP/CIP familymembers. Post-translational modifications: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex. Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF(SKP1-cullin-F-box) protein ligase complex containing FBXO31.SCF-type ubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulingene regions. Activation of CCND1 may be oncogenic by directlyaltering progression through the cell cycle. Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15) withthe parathyroid hormone (PTH) enhancer. Defects in CCND1 are a cause of multiple myeloma (MM)[MIM:254500]. MM is a malignant tumor of plasma cells usuallyarising in the bone marrow and characterized by diffuse involvementof the skeletal system, hyperglobulinemia, Bence-Jones proteinuriaand anemia. Complications of multiple myeloma are bone pain,hypercalcemia, renal failure and spinal cord compression. Theaberrant antibodies that are produced lead to impaired humoralimmunity and patients have a high prevalence of infection.Amyloidosis may develop in some patients. Multiple myeloma is partof a spectrum of diseases ranging from monoclonal gammopathy ofunknown significance (MGUS) to plasma cell leukemia. Note=Achromosomal aberration involving CCND1 is found in multiplemyeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Similarity: Belongs to the cyclin family. Cyclin D subfamily. SWISS: P25322 Gene ID: 595 Database links: Entrez Gene: 595 Human Entrez Gene: 12443 Mouse Entrez Gene: 58919 Rat Omim: 168461 Human SwissProt: P24385 Human SwissProt: P25322 Mouse SwissProt: P39948 Rat Unigene: 523852 Human Unigene: 667996 Human Unigene: 273049 Mouse Unigene: 22279 Rat 細胞周期素D1蛋白（Cyclin D1）是細胞周期中的重要調控因子，它作用于細胞周期的G1→S期調控點，為G1期的限速步驟。細胞周期蛋白D1-Cyclin D1的過度表達使細胞周期G1期縮短，細胞生長對有絲分裂原和粘附信號的需求降低，最終引發腫瘤的發生。該抗原的氨基酸序列抗原決定簇-結合位點，我們選在了細胞質的粗面內質網。越來越多的研究表明。CyclinD1在正常細胞周期及腫瘤的調節中起著重要作用。周期素D1/Bcl-1屬于細胞周期調控蛋白家族成員之一，在細胞周期從G1進入S期中起到重要作用。周期素D1的過度表達與癌癥的早發、腫瘤的進展和轉移相關。該抗體可用于細胞周期方面的研究，
產品圖片	Sample: A549 Lysate at 40 ug Primary: Anti-CyclinD1 (bs-0623R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/10000 dilution Predicted band size: 32 kD Observed band size: 35 kD Sample: Mcf-7(Human) Cell Lysate at 30 ug Primary: Anti-Cyclin D1 (bs-0623R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 32 kD Observed band size: 32 kD Sample: A549 Cell (Human) Lysate at 30 ug Primary: Anti-Cyclin D1 (bs-0623R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 32 kD Observed band size: 35 kD Sample: Lane 1: Small intestine (Mouse) Lysate at 40 ug Lane 2: U251 (Human) Cell Lysate at 30 ug Lane 3: HT1080 (Human) Cell Lysate at 30 ug Primary: Anti-Cyclin D1 (bs-0623R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 34 kD Observed band size: 34 kD Paraformaldehyde-fixed, paraffin embedded (Rat liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cyclin D1) Polyclonal Antibody, Unconjugated (bs-0623R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Paraformaldehyde-fixed, paraffin embedded (Human cervical cancer); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cyclin D1) Polyclonal Antibody, Unconjugated (bs-0623R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Paraformaldehyde-fixed, paraffin embedded (Rat esophageal); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cyclin D1) Polyclonal Antibody, Unconjugated (bs-0623R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Paraformaldehyde-fixed, paraffin embedded (Rat testis); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cyclin D1) Polyclonal Antibody, Unconjugated (bs-0623R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Paraformaldehyde-fixed, paraffin embedded (rat liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cyclin D1) Polyclonal Antibody, Unconjugated (bs-0623R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Paraformaldehyde-fixed, paraffin embedded (rat kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cyclin D1) Polyclonal Antibody, Unconjugated (bs-0623R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Tissue/cell: human endometrium carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-Cyclin D1 Polyclonal Antibody, Unconjugated(bs-0623R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining Tissue/cell: human placenta tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-Cyclin D1 Polyclonal Antibody, Unconjugated(bs-0623R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining Tissue/cell:MCF7 cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (Cyclin D1) polyclonal Antibody, Unconjugated (bs-0623R) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei. Blank control: RSC96(blue), the cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with ice-cold 90% methanol for 30 min on ice. Isotype Control Antibody: Rabbit IgG(orange) ; Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA ; Primary Antibody Dilution: 1μg in 100 μL1X PBS containing 0.5% BSA(green).